Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

0.5901 +0.0369 (+6.67%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics to Present at Biomarkers Europe 2023
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
Via ACCESSWIRE
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Inc. (NASDAQ: ALLR) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Allarity Therapeutics (NASDAQ: ALLR) Reports Early Success in Phase 2 Trial for Breast Cancer Drug IXEMPRA®
Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the 
Via Spotlight Growth
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023
Via ACCESSWIRE
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial
Via ACCESSWIRE
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform
Once brought into its pipeline, Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year,... 
Via TheNewswire.com
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough
New York, United States - 08-11-2022 (PR Distribution™) - 
Via PR Distribution
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.